4th Quarter - Report
VENN STRATEGIES for ELI LILLY AND COMPANY
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Firm
Client
Income
$30,000
Expenses
—
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 21, 2020 | $30,000 | Replaced |
| 4th Quarter - Amendment | Jul 6, 2026 | $30,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
General Healthcare Issues pertaining to Eli Lilly and Company, including but not limited to drug pricing, importation and innovation policies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| NATASCHA CUMBERLIDGE | — |
| AUSTIN TYLER ROBERTS | — |
| STEPHANIE SILVERMAN | — |
| MICHAEL SPIRA | — |
| ELISE TOLLEFSON New | Legislative Director, Rep. Tom Reed; Legislative Director, Rep. Randy Hultgren |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.